Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
112
NCT02262338
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 30, 2015
Completion: Mar 27, 2017
NCT02371226
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
Start: Jul 31, 2015
Completion: Feb 1, 2017
NCT03053089
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
Phase: Phase 1/2
Start: Oct 31, 2015
Completion: Feb 1, 2018
NCT02597114
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
Start: Nov 30, 2015
Completion: Aug 2, 2018
NCT03071341
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
Start: Oct 31, 2016
NCT07176351
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Phase: Phase 4
Role: Collaborator
Start: Dec 31, 2025
Completion: Feb 28, 2027